US Pharma MarketingExclusive: Waypoint Bio raises $20M to run three CAR-T trials in China
New York City-based startup Waypoint Bio has raised $20 million in series A financing to test multiple cell therapies in China. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for…
New York City-based startup Waypoint Bio has raised $20 million in Series A financing to test multiple cell therapies in China, the company told Endpoints News.
The move takes advantage of China's system for testing ...
Source: Endpoints News